- **Inspira Technologies** announced that its **HYLA™ blood sensor** achieved **97.35% accuracy** in its latest performance testing phase.  **[1837493_0001213900-25-086686_ea025677301ex99-1_inspira.htm:0]** 
- These results represent a significant advancement and confirm the device's readiness for **U.S. Food and Drug Administration (FDA) submission for clearance**.  **[1837493_0001213900-25-086686_ea025677301ex99-1_inspira.htm:0]** 
- The **HYLA sensor** provides **continuous, non-invasive monitoring** of blood parameters and is being developed as a **standalone device** to penetrate the broader disposables market, leveraging a planned **razor-and-blade recurring revenue model**.  **[1837493_0001213900-25-086686_ea025677301ex99-1_inspira.htm:0]**

Inspira Technologies Announces HYLA Blood Sensor Accuracy Results and FDA Submission Progress

- Inspira Technologies OXY B.H.N. announced **pivotal results** for its HYLA blood sensor, achieving **97.35% accuracy** in its latest performance testing phase.  **[1837493_de711009afee4ad6835ef3dd115f713a_0]** 
- These results will support the **upcoming U.S. Food and Drug Administration (FDA) submission** for clearance and confirm the device's readiness for regulatory pathways in the U.S. and Europe.  **[1837493_de711009afee4ad6835ef3dd115f713a_0]** 
- The HYLA blood sensor provides **continuous, second-by-second, non-invasive monitoring** of key blood parameters, designed to enable real-time, life-saving decisions in critical care.  **[1837493_de711009afee4ad6835ef3dd115f713a_0]** **[1837493_de711009afee4ad6835ef3dd115f713a_1]** 
- While primarily designed for integration with Inspira's ART device line, the HYLA sensor is also being developed as a **standalone device** to penetrate the **broader disposables market** using a **razor-and-blade recurring revenue model**.  **[1837493_de711009afee4ad6835ef3dd115f713a_1]**

Inspira Technologies OXY B.H.N. (IINN)